On Wednesday, Jefferies reiterated its Buy rating and $13.00 price target for Bausch Health Companies (NYSE:BHC), emphasizing the importance of management providing clear guidance to investors. The firm addressed the recent misinformation regarding Bausch Health's financial status, referring to a report that falsely claimed the company was negotiating a pre-packaged Chapter 11 bankruptcy filing, which Bausch Health denied.
The analyst highlighted the company's responsibility to offer investors better clarity on its future, especially considering the planned full separation of its eye health business, Bausch + Lomb. The separation is seen as a key move that could add value for Bausch Health shareholders. The firm pointed out several recent developments that have complicated the company's outlook, including legal victories and new litigations, as well as the formation of a creditor cooperative.
These events have reportedly created uncertainty among investors and have weighed on the company's shares in recent months. Jefferies believes that these issues have obscured the path forward for Bausch Health, including the potential barriers to the spin-off, whether they be related to litigation, leverage, or other factors.
The price target of $13 is based on a pro forma 6x multiple on the firm's calendar year 2025 adjusted EBITDA estimate for the RemainCo and the estimated valuation of an 80% Bausch + Lomb distribution. The calculations take into account the current market value of Bausch + Lomb and the projected distribution of Bausch + Lomb shares to Bausch Health shareholders.
In other recent news, Bausch Health Companies Inc. has refuted bankruptcy speculation and reported a 4% increase in revenues for the first quarter of 2024, reaching $1.05 billion, with a 9% rise in adjusted EBITDA to $504 million. The company is also progressing its R&D initiatives and working towards the full separation of its Bausch+Lomb segment. Concurrently, Bausch Health has initiated a patent infringement lawsuit against Norwich Pharmaceuticals, Inc., concerning its intention to market a generic version of XIFAXAN®, a treatment for irritable bowel syndrome with diarrhea.
An RBC Capital analyst recently downgraded Bausch Health's price target to $10.00 from the previous $11.00 due to the company's EBITDA falling short of expectations, but the company's rating remained at Sector Perform. These are recent developments that investors should consider.
InvestingPro Insights
As Bausch Health Companies (NYSE:BHC) continues to navigate through its challenges, insights from InvestingPro highlight several key financial metrics and projections that investors may find valuable. With a market capitalization of approximately $2.09 billion, Bausch Health's valuation suggests a strong free cash flow yield, which could be a sign of the company's ability to generate cash and potentially enhance shareholder value. Despite not paying a dividend, which reflects a reinvestment strategy or the need to conserve cash, analysts are optimistic, predicting profitability for the company this year. This is particularly noteworthy as the company was not profitable over the last twelve months.
The company's revenue has shown a solid growth rate of 10.01% over the last twelve months as of Q1 2024, which could be indicative of Bausch Health's ability to expand its market share and improve its financial stability. Additionally, the gross profit margin stands at a healthy 70.81%, suggesting that the company is efficient in its operations and cost management. These metrics, along with the expected net income growth, may provide a more comprehensive picture of the company's financial health and support the positive outlook shared by Jefferies.
For investors seeking to delve deeper into Bausch Health's financials and future prospects, there are additional InvestingPro Tips available, offering a more granular analysis of the company's performance and potential. By using the coupon code PRONEWS24, investors can get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription to access these insights. With the next earnings date approaching on August 1, 2024, these insights could be particularly timely for those looking to make informed decisions regarding Bausch Health's stock.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.